A Message from the President Dear Colleagues, While the global coronavirus pandemic has held our attention since March, this edition of the President’s Message will focus on the greater mission that brings us all together. June is Cancer Immunotherapy Awareness Month™ , and so, first...
SITC Congratulates 2020 Election Winners The Society for Immunotherapy of Cancer (SITC) is pleased to share the results of the 2020 SITC Election. The candidates who received the most votes during the election, which took place May 6-20, 2020, are: Newly Elected SITC Vice President ...
The rapid rise to fame of immuno-oncology (IO) drugs has generated unprecedented interest in the industry, patients and doctors, and has had a major impact in the treatment of most cancers. An interesting aspect in the clinical development of many IO agents is the increasing reliance on...
As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)...
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, demonstrates predictive biomarker potential for the identification of patients with cancer most likely to respond to immune checkpoint inhibitors. TMB is optimally calculated...
header image SITC Cancer Immunotherapy Guidelines Expert Panels are comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations,...
header image The coronavirus (COVID-19) pandemic has affected all aspects of healthcare and the oncology and immuno-oncology communities may face unique challenges in regards to patient care. As immuno-oncology practitioners treat patients during the pandemic, it has also become apparent that...
Response criteria developed when cytotoxic chemotherapy was the predominant therapeutic modality to treat patients with cancer, do not capture the full spectrum of tumor response patterns observed with anti-PD-1/PD-L1 antibody treatment. iRECIST was developed to capture both typical and atypical...
Quality measures are important because they can help improve and standardize the delivery of cancer care among healthcare providers and across tumor types. In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, defining...
Presentation slides and video from the 2020 Advances in Cancer Immunotherapy TM - Charleston, SC, held on February 1, 2020 are available here. Program Organizers David M. Neskey, MD – MUSC Hollings Cancer Center Chrystal M. Paulos, PhD – Medical University of South Carolina ...
19 attachments
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us